Clinical Conundrums: Choosing the Best Management Approaches in Patients With Ovarian Cancer Thomas J. Herzog, MD Director, Division of Gynecologic Oncology. - ppt download
PPT - AGO-OVAR DESKTOP III (Protocol AGO - OVAR OP.4) PowerPoint Presentation - ID:3272978
This #ASCO20 was notable for two major trials exploring secondary cytoreductive surgery in recurrent #ovariancancer - DESKTOP III and SOC -1 #ASCO20 # - Thread from Shannon Westin @ShannonWestin - Rattibha
Dr. STEFANY CARDOSO FARIA - MÉDICO ONCOLOGISTA: #ASCO 2017 Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20
Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial - The Lancet
Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial - The Lancet Oncology
The Next Steps in Improving the Outcomes of Advanced Ovarian Cancer - Mark R Openshaw, Christina Fotopoulou, Sarah Blagden, Hani Gabra, 2015
Secondary cytoreductive surgery for recurrent ovarian cancer improves overall survival - BJMO
Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial - The Lancet Oncology
PPT - AGO-OVAR DESKTOP III (Protocol AGO - OVAR OP.4) PowerPoint Presentation - ID:1402011
Last improvements in advanced ovarian cancer treatment | Com&Co Group
A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study
Cancers | Free Full-Text | Diagnostic and Therapeutic Pathway of Advanced Ovarian Cancer with Peritoneal Metastases
Cytoreductive surgery before chemotherapy benefits women with recurrent ovarian cancer
Dr. STEFANY CARDOSO FARIA - MÉDICO ONCOLOGISTA: #ASCO 2017 Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20
New Data Support Debulking to Prolong Survival in Women With Platinum-Sensitive Recurrent Ovarian Cancer | ASCO Daily News
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer | NEJM
Epithelial ovarian cancer - The Lancet
Frontiers | Ovarian Real-World International Consortium (ORWIC): A multicentre, real-world analysis of epithelial ovarian cancer treatment and outcomes
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer | NEJM
